Formulary systems and pharmacy and therapeutics committees in the Western Pacific Region: Exploring two Basel Statements

American Journal of Health-System Pharmacy

Volumn 70, Issue 11, 2013, Pages 967-979

  Penm, Jonathan ^a,b   Chaar, Betty ^b   Dechun, Jiang ^c   Moles, Rebekah ^b  

^a SYDNEY EYE HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADVISORY COMMITTEE; ARTICLE; CLINICAL PHARMACY; DRUG FORMULARY; HOSPITAL PHARMACY; HOSPITAL POLICY; HUMAN; MEDICATION THERAPY MANAGEMENT; OFF LABEL DRUG USE; PATIENT CARE; PHARMACEUTICAL CARE; PHARMACY AND THERAPEUTICS COMMITTEE; PRACTICE GUIDELINE; INFORMATION PROCESSING; PACIFIC ISLANDS; PROCEDURES; PUBLICATION; STANDARDS; STATISTICS AND NUMERICAL DATA; SWITZERLAND;

DATA COLLECTION; FORMULARIES, HOSPITAL; HUMANS; PACIFIC ISLANDS; PHARMACY AND THERAPEUTICS COMMITTEE; PHARMACY SERVICE, HOSPITAL; SWITZERLAND;

EID: 84892757039     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp120396     Document Type: Article

References (57)

1. World Health Organization. Continuity and change: implementing the third WHO medicines strategy 2008-2013. www.who.int/medicines/publications/medstrategy08-13/en/index.html (accessed 2013 Jan 13).
2. Tyler LS, Cole SW, May JR et al. ASHP guidelines on the pharmacy and therapeutics committee and the formulary system. Am J Health-Syst Pharm. 2008; 65:1272-83.
3. Chinburapa V, Larson LN, Brucks M et al. Physician prescribing decisions: the effects of situational involvement and task complexity on information acquisition and decision making. Soc Sci Med. 1993; 36:1473-82.
4. Glossary of terms. Am J Health-Syst Pharm. 2009; 66(suppl 3):S67-70.
5. World Health Organization. Country pharmaceutical situations: fact book on WHO level 1 indicators. http://apps.who.int/medicinedocs/documents/s16874e/s16874e.pdf (accessed 2013 Jan 15).
6. Backman G, Hunt P, Khosla R et al. Health systems and the right to health: an assessment of 194 countries. Lancet. 2008; 372:2047-85.
7. World Health Organization. Guide to good prescribing - a practical manual. http://apps.who.int/medicinedocs/en/d/Jwhozip23e/ (accessed 2013 Jan 15).
8. Quick JD. Essential medicines twenty-five years on: closing the access gap. Health Policy Plan. 2003; 18:1-3.
9. Thürmann PA, Harder S, Steioff A. Structure and activities of hospital drug committees in Germany. Eur J Clin Pharmacol. 1997; 52:429-35.
10. Sloan FA, Gordon GS, Cocks DL. Hospital drug formularies and use of hospital services. Med Care. 1993; 31:851-67.
11. Kwan J. Hospital formularies restrict evidence based practice. BMJ. 2005; 331:515. Letter.
12. Franklin GA. The driving force in hospital formularies: economics versus efficacy. Am J Surg. 2003; 186:55S-60S.
13. The truth about hospital formularies: survey shows many myths still exist 15 years later. Pa Nurse. 2005; 60:30,33.
14. Rucker TD, Schiff G. Drug formularies: myths-in-formation. Med Care. 1990; 28:928-42.
15. Lucarelli CD. Formulary management strategies for type 3 serotonin receptor antagonists. Am J Health-Syst Pharm. 2003; 60(suppl 1):S4-11.
16. Longyhore DS, Stockton CM, Thomas MR. Lipid profile changes associated with changing available formulary statins: removing higher potency agents. Am J Manag Care. 2009; 15:409-14.
17. Guglielmo BJ, Dudas V, Maewal I et al. Impact of a series of interventions in vancomycin prescribing on use and prevalence of vancomycin-resistant enterococci. Jt Comm J Qual Patient Saf. 2005; 31:469-75.
18. Landman D, Chockalingam M, Quale JM. Reduction in the incidence of methicillin-resistant Staphylococcus aureus and ceftazidime-resistant Klebsiella pneumoniae following changes in a hospital antibiotic formulary. Clin Infect Dis. 1999; 28:1062-6.
19. Baker JA, Lant AF, Sutters CA. Seventeen years' experience of a voluntarily based drug rationalisation programme in hospital. BMJ. 1988; 297:465-9.
20. Feely J, Chan R, Cocoman L et al. Hospital formularies: need for continuous intervention. BMJ. 1990; 300:28-30.
21. Odedina FT, Sullivan J, Nash R et al. Use of pharmacoeconomic data in making hospital formulary decisions. Am J Health-Syst Pharm. 2002; 59:1441-4.
22. Jenkings KN, Barber N. What constitutes evidence in hospital new drug decision making? Soc Sci Med. 2004; 58:1757-66.
23. Späth HM, Charavel M, Morelle M et al. A qualitative approach to the use of economic data in the selection of medicines for hospital formularies: a French survey. Pharm World Sci. 2003; 25:269-75.
24. Pedersen CA, Schneider PJ, Scheckelhoff DJ. ASHP national survey of pharmacy practice in hospital settings: prescribing and transcribing - 2010. Am J Health-Syst Pharm. 2011; 68:669-88.
25. Mittmann N, Knowles S. A survey of pharmacy and therapeutic committees across Canada: scope and responsibilities. Can J Clin Pharmacol. 2009; 16:e171-7.
26. Tan EL, Day RO, Brien JE. Prioritising drug and therapeutics committee (DTC) decisions: a national survey. Pharm World Sci. 2007; 29:90-6.
27. Tordoff JM, Norris P, Kennedy J et al. Quality use of medicines activities in New Zealand hospitals from 2000 to 2002. N Z Med J. 2005; 118:U1259.
28. Chang S, Wong JW, Wong CW et al. Overview of the hospital formulary systems in Hong Kong. Princess Margaret Hospital as a baseline. Ann Pharmacother. 1997; 31:1526-31.
29. Surugue J, Gala TM. EAHP 2005 survey. www.eahp.eu/sites/default/files/files/EAHP%202005%20survey%20V07609TMG%20A4.pdf (accessed 2013 Apr 1).
30. Pedersen CA, Schneider PJ, Scheckelhoff DJ. ASHP national survey of pharmacy practice in hospital settings: prescribing and transcribing - 2004. Am J Health-Syst Pharm. 2005; 62:378-90.
31. Rascati KL. Survey of formulary system policies and procedures. Am J Hosp Pharm. 1992; 49:100-3.
32. World Health Organization. How to develop a national formulary based on the WHO model formulary: a practical guide. http://apps.who.int/medicinedocs/en/d/Js6171e/ (accessed 2013 Jan 15).
33. Rucker TD, Visconti JA. How effective are drug formularies? A descriptive and normative study. Washington, DC: ASHP Research and Education Foundation; 1978.
34. Rucker TD, Visconti JA. Hospital formularies: organizational aspects and supplementary components. Am J Hosp Pharm. 1976; 33:912-7.
35. Plumridge RJ, Stoelwinder JU, Berbatis CG. Improving patient care and pharmacy management: the effect of hospital formularies. Drug Intell Clin Pharm. 1984; 18:652-6.
36. Weekes LM, Brooks C. Drug and therapeutics committees in Australia: expected and actual performance. Br J Clin Pharmacol. 1996; 42:551-7.
37. Pedersen CA, Schneider PJ, Santell JP. ASHP national survey of pharmacy practice in hospital settings: prescribing and transcribing - 2001. Am J Health-Syst Pharm. 2001; 58:2251-66.
38. Laing RO, Hogerzeil HV, Ross-Degnan D. Ten recommendations to improve the use of medicines in developing countries. Health Policy Plan. 2001; 16:13-20.
39. The Basel Statements on the future of hospital pharmacy. Am J Health-Syst Pharm. 2009; 66(suppl 3):S61-6.
40. World Health Organization. Drug and therapeutics committees: a practical guide. http://apps.who.int/medicinedocs/en/d/Js4882e/ (accessed 2013 Jan 15).
41. Durán-García E, Santos-Ramos B, Puigventos-Latorre F et al. Literature review on the structure and operation of pharmacy and therapeutics committees. Int J Clin Pharm. 2011; 33:475-83.
42. Doloresco F, Vermeulen LC. Global survey of hospital pharmacy practice. Am J Health-Syst Pharm. 2009; 66(suppl 3):S13-9.
43. Penm J, Chaar B, Moles R. Developing a validated survey to assess the Basel Statements: the Western Pacific Region's response. Int Pharm J. 2010; 26:34-8.
44. Penm J, Chaar B, Moles R. Validating a hospital medicines formulary survey in the Western Pacific Region: a global hospital pharmacy initiative based on the Basel Statements. Res Soc Adm Pharm. 2012; 8:298-308.
45. World Health Organization. Western Pacific country health information profiles: 2009 revision. www.wpro.who.int/publications/PUB-9789290614425/en/index.html (accessed 2013 Jan 15).
46. Beaton DE, Bombardier C, Guillemin F et al. Guidelines for the process of cross-cultural adaptation of self-report measures. Spine. 2000; 25:3186-91.
47. Krejcie RV, Morgan DW. Determining sample size for research activities. Educ Psychol Meas. 1970; 30:607-10.
48. World Health Organization. District health facilities: guidelines for development and operations. http://apps.who.int/bookorders/anglais/detart1.jsp?codlan=1&codcol=51&codcch=22 (accessed 2013 Jan 15).
49. World Bank. Country and lending groups. http://data.worldbank.org/about/country-classifications/country-and-lending-groups (accessed 2012 Apr 14).
50. Tabachnick BG, Fidell LS. Using multivariate statistics. 5th ed. Boston: Allyn and Bacon; 2007.
51. Martin DK, Hollenberg D, MacRae S et al. Priority setting in a hospital drug formulary: a qualitative case study and evaluation. Health Policy. 2003; 66:295-303.
52. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med. 2006; 166:1021-6.
53. Turner S, Nunn AJ, Fielding K et al. Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paediatr. 1999; 88:965-8.
54. Neubert A, Dormann H, Weiss J et al. The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients. Drug Saf. 2004; 27:1059-67.
55. Promoting Rational Medicines Use and Drug and Therapeutics Committees. Arlington, VA: Management Sciences for Health/Strengthening Pharmaceutical Systems (MSH/SPS) Program; 2010.
56. Scott A, Jeon SH, Joyce CM et al. A randomised trial and economic evaluation of the effect of response mode on response rate, response bias, and item non-response in a survey of doctors. BMC Med Res Methodol. 2011; 11:126.
57. Denscombe M. Item non-response rates: a comparison of online and paper questionnaires. Int J Soc Res Methodol. 2009; 12:281-91.